Company restructures business into three distinct divisions that include in
vitro diagnostics, cancer therapeutics and China-based integrated
TUSTIN, Calif., Oct. 14 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc. (Amex: ADL), a vertically integrated pharmaceutical company with major operations in China and the US, today announced it has restructured its business into three distinct divisions to better reflect the Company's operational focus on becoming a world-class, diversified pharmaceutical company.
The new divisions include an In Vitro Diagnostics (IVD) division specifically focused on accelerating AMDL's market launch for the AMDL-ELISA DR-70(R) (FDP) cancer test; a Cancer Therapeutics division specifically focused on accelerating research for its Combination Immunogene Therapy (CIT) technology; and a China-based Integrated Pharmaceuticals division focused on the continued manufacturing, sales and distribution of AMDL's broad range of generic, specialty and branded pharmaceutical products.
AMDL will continue to execute its 2008 business plan with a focus on
achieving its stated financial target of a 100% increase in sales over
2007. Additionally, under this new operational structure, AMDL will
aggressively work to:
-- Establish the IVD division for DR-70 with a structural platform for
funding the division through a potential joint-venture partnership(s)
or selling the division as a stand-alone business;
-- Establish the Cancer Therapeutics division with a structural platform
for funding the division through a potential joint-venture
partnership(s) or selling the division as a stand-alone business;
-- Continue accelerating the manufacturing, sales & marketing of AMDL's
diverse China-based pharmaceutical product portfolio through the
Integrated Pharmaceuticals division; and,
-- Leverage AMDL's current assets and resources to drive future growth.
"Segmenting AMDL's operations into these three distinct divisions provides us with greater market focus, increased flexibility across our diverse product portfolio, and a solid platform to successfully execute AMDL's key business goals," commented Mr. Gary Dreher, President and CEO of AMDL. "We've achieved significant growth in sales and gross profits over the past 18 months and believe this refinement will strengthen AMDL's long-term growth position as a leading developer, manufacturer and supplier of high-quality diagnostic and pharmaceutical products."
For additional information on AMDL and its diversified product portfolio visit the Company's website at http://www.amdl.com or contact AMDL Investor Relations at 206.310.5323.
Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs approximately 320 people in the U.S. and China. The Company has an additional 4 pharmaceutical and diagnostic products under review by various regulatory authorities.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995: The statements contained in this document include certain
predictions and projections that may be considered forward-looking
statements under securities law. These statements involve a number of
important risks and uncertainties that could cause actual results to differ
materially including, but not limited to, the performance of joint venture
partners, as well as other economic, competitive and technological factors
involving the Company's operations, markets, services, products, and
prices. With respect to AMDL Inc., except for the historical information
contained herein, the matters discussed in this document are
forward-looking statements involving risks and uncertainties that could
cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties related to
the Company's access to additional capital, competition and dependence on
(Tel :) 206.310.5323
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved